Psychiatric Research Unit, Region Zealand Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2016
NCT02451293
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Psychiatric Research Unit, Region Zealand, Denmark

Active Ingredients

Drugs in Phase 3 Trials (1)

melatonin (1 trial)

Drugs in Other Trials (1)

creatine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Dyssomnias (Phase 3)

Parasomnias (Phase 3)

Sleep Wake Disorders (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2